Colin Walsh, Ph.D. joined Qiming Venture Partners USA in April 2019 and is based in South San Francisco, CA. He currently serves on the boards of Elevation Oncology and Korro Bio and is a board observer of Amphivena Therapeutics and Icosavax.
Before joining Qiming in 2019, Colin was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to NanoDimension, he held a number of roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.